Generics Worry Fed. Circ. Blew Up 'Routine' Labeling Practice
The Federal Circuit's recent decision to revive a $235 million induced infringement verdict against Teva has left generic-drug makers scared that they'll be effectively barred from selling patent-protected drugs for approved,...To view the full article, register now.
Already a subscriber? Click here to view full article